Landscape review of global real-world data sources for studying medication use in pregnancy and lactation that support regulatory decision making

被引:2
作者
Davis, Kourtney [1 ]
Yost, Emily [1 ,6 ]
Brauneis, Jacquelyne [2 ]
Krumme, Alexis [1 ]
Geldhof, Anja [3 ]
Tuck, Astrud [4 ]
Sylvester, Shirley [5 ]
Ephross, Sara [2 ]
机构
[1] Janssen Res & Dev LLC, Global Epidemiol, Raritan, NJ USA
[2] Syneos Hlth, Real World & Late Phase, Morrisville, NC USA
[3] Janssen Bol BV, Med Affairs, Leiden, Netherlands
[4] Janssen Res & Dev LLC, Data Sci, New Brunswick, NJ USA
[5] Johnson & Johnson, Global Publ Hlth, Zug, Switzerland
[6] Janssen Res & Dev LLC, Dept Epidemiol, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
关键词
breastfeeding; mother-infant; pharmacoepidemiology; pregnancy; real-world data;
D O I
10.1002/pds.5711
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose: Most pregnant people take at least one medication during gestation or while breastfeeding, however data are lacking on the safety of medication use in these populations. We conducted a landscape review of real-world data sources specific to medication use in pregnancy and breastfeeding populations that have met, or have potential to meet, health authorities' requirements for post-authorization safety studies.Methods: A 2-phase approach identified data sources from literature, publicly available registers of non-interventional post-authorization studies of pregnant women, existing database inventories, and emerging data sources known to the authors.Results: Required key attributes were assessed according to current regulatory guidance, resulting in selection of 49 suitable data sources. All global regions were represented, with North America (37%) and Europe (33%) most common; 12% of the data sources included pregnancy information from low-to middle-income countries. Administrative healthcare claims (25%) and electronic healthcare records (21%) comprised the largest types of data sources. Across data sources, 53% were managed by national or regional governments, 27% by industry, and 20% by academic institutions. Maternal age, diagnoses, prenatal care, and reproductive history were available in most, whereas fewer included demographic data (e.g., race/ethnicity). Breastfeeding data were collected in 37% of the final data sources.Conclusion: We conducted a systematic approach to data source evaluation of pregnancy and breastfeeding to be used as a resource for investigators to consider when designing pregnancy-related research studies to satisfy regulatory requirements.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Real-world data in Saudi Arabia: Current situation and challenges for regulatory decision-making
    Alnofal, Fatemah A.
    Alrwisan, Adel A.
    Alshammari, Thamir M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (10) : 1303 - 1306
  • [2] The application of real-world evidence in drug regulatory decision-making
    Wicherski, Julia
    Haenisch, Britta
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2024, 67 (02) : 255 - 256
  • [3] Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms
    Burcu, Mehmet
    Dreyer, Nancy A.
    Franklin, Jessica M.
    Blum, Michael D.
    Critchlow, Cathy W.
    Perfetto, Eleanor M.
    Zhou, Wei
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (10) : 1228 - 1235
  • [4] Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making
    Sola-Morales, Oriol
    Siguroardottir, Katla
    Akehurst, Ron
    Murphy, Linda A.
    Mestre-Ferrandiz, Jorge
    Cunningham, David
    de Pouvourville, Gerard
    VALUE IN HEALTH, 2023, 26 (04) : 32 - 42
  • [5] Real-world evidence to support regulatory decision making: New or expanded medical product indications
    Franklin, Jessica M.
    Liaw, Kai-Li
    Iyasu, Solomon
    Critchlow, Cathy W.
    Dreyer, Nancy A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (06) : 685 - 693
  • [6] ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): a screening tool to assess the potential for real-world data sources to support creation of credible real-world evidence for regulatory decision-making
    Berger, Marc L.
    Crown, William H.
    Li, Jim Z.
    Zou, Kelly H.
    HEALTH SERVICES AND OUTCOMES RESEARCH METHODOLOGY, 2024, 24 (03) : 348 - 365
  • [7] The relevance of the real-world evidence in research, clinical, and regulatory decision making
    Costa, Valton
    Custodio, Marcelo Graziano
    Gefen, Eran
    Fregni, Felipe
    FRONTIERS IN PUBLIC HEALTH, 2025, 13
  • [8] The use of real-world data/evidence in regulatory submissions
    Song, Fuyu
    Zang, Chenxuan
    Ma, Xinyi
    Hu, Sifan
    Sun, Qiqing
    Chow, Shein-Chung
    Sun, Hongqiang
    CONTEMPORARY CLINICAL TRIALS, 2021, 109
  • [9] Real-World Evidence: A Review of Real-World Data Sources Used in Orthopaedic Research
    Hak, David J.
    Mackowiak, John I.
    Irwin, Debra E.
    Aldridge, Molly L.
    Mack, Christina D.
    JOURNAL OF ORTHOPAEDIC TRAUMA, 2021, 35 : S6 - S12
  • [10] Transferability of real-world data across borders for regulatory and health technology assessment decision-making
    Jaksa, Ashley
    Arena, Patrick J.
    Chan, Kelvin K. W.
    Ben-Joseph, Rami H.
    Jonsson, Pall
    Campbell, Ulka B.
    FRONTIERS IN MEDICINE, 2022, 9